Denali Therapeutics Inc. DNLI
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 155.26% | -2.77% | 3.40% | -12.02% | -18.39% |
| Total Depreciation and Amortization | 16.29% | 13.35% | 17.09% | 44.41% | 70.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -867.79% | 19.03% | 3.73% | 18.75% | 42.32% |
| Change in Net Operating Assets | -276.37% | -98.36% | -25.36% | -52.48% | -120.50% |
| Cash from Operations | -9.46% | -28.82% | 0.20% | -17.71% | -81.43% |
| Capital Expenditure | -173.29% | 81.18% | 51.44% | 70.07% | 135.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -413.18% | -163.67% | 306.81% | -87.43% | -42.12% |
| Cash from Investing | -72.00% | -165.90% | 403.84% | -87.94% | -38.25% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 98.38% | 99.14% | 99.61% | 99.81% | 94.33% |
| Issuance of Common Stock | 356.09% | 269.85% | 3,103.53% | 22,053.38% | -89.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 433.16% | 823.23% | 5,922.54% | 4,709.72% | 95.81% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -96.36% | -320.86% | 256.50% | 35.62% | -414.87% |